Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

S2155000

Sulfasalazine

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

2-Hydroxy-5-{{4-[(2-pyridinylamino)sulfonyl]phenyl}azo}benzoic acid, 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic acid, Salicylazosulfapyridine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H14N4O5S
Número de CAS:
599-79-1
Peso molecular:
398.39
Beilstein:
356241
Número MDL:
MFCD00057363
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329824508
En este momento no podemos mostrarle ni los precios ni la disponibilidad

familia API

sulfasalazine

mp

260-265 °C (dec.) (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

OC(=O)c1cc(ccc1O)\N=N\c2ccc(cc2)S(=O)(=O)Nc3ccccn3

InChI

1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+

Clave InChI

NCEXYHBECQHGNR-QZQOTICOSA-N

Información sobre el gen

human ... ALOX5(240) , PTGS1(5742) , PTGS2(5743)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Sulfasalazine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Pictogramas

Health hazardEnvironment
GHS08,GHS09

Palabra de señalización

Danger

Frases de peligro

H317,H334,H351,H361f,H411

Clasificaciones de peligro

Aquatic Chronic 2 - Carc. 2 - Repr. 2 - Resp. Sens. 1 - Skin Sens. 1

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Junmin Chen et al.
The Journal of rheumatology, 33(4), 722-731 (2006-04-04)
To evaluate the efficacy and toxicity of sulfasalazine (SSZ) for the treatment of ankylosing spondylitis (AS). We searched randomized and quasi-randomized trials in any language comparing SSZ with placebo in treatment of AS. Two reviewers independently selected the studies and
J R O'Dell
Rheumatic diseases clinics of North America, 24(3), 465-477 (1998-08-26)
Combinations of DMARDs are currently used to treat rheumatoid arthritis by almost all rheumatologists. This article reviews the published data on the triple combination of methotrexate, sulfasalazine, and hydroxychloroquine, discusses caveats for clinical use, compares efficacy of different combinations, and
Shekoufeh Nikfar et al.
Digestive diseases and sciences, 54(6), 1157-1170 (2008-09-05)
Historically, sulfasalazine (SSZ) and 5-aminosalicylates (5-ASAs) have been a mainstay of mild-to-moderate ulcerative colitis (UC) remission induction and maintenance therapy. Considering the pivotal role of intestinal microbial flora in pathophysiology of UC and antimicrobial activity of sulfapyridine, we hypothesized that
James Dale et al.
Nature clinical practice. Rheumatology, 3(8), 450-458 (2007-08-01)
Early aggressive treatment of rheumatoid arthritis is associated with improved disease control, slower radiological progression and improved functional outcomes. Tumor necrosis factor blocking therapy is effective but there remain concerns about long-term risks. Combining disease-modifying antirheumatic drugs (DMARDs) is a
Frederick A Jakobiec et al.
American journal of ophthalmology, 158(4), 838-844 (2014-07-19)
To evaluate the clinical and immunopathologic features of 2 patients with bilateral dacryoadenitis associated with regional enteritis. Retrospective, clinicopathologic study. Clinical records, photographs, and imaging studies were reviewed and microscopic sections of lacrimal gland biopsy samples were critically re-evaluated. The
Ver todos los artículos relacionados

Preguntas

Revisiones

Sin puntuación

Filtros activos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico